← Home
The Peter Attia Drive · September 14, 2026 · 1h 59m

#407 ‒ Preventing cardiovascular and Alzheimer's disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.

Michael Davidson
Show Notes

Cardiologist Michael Davidson joins Peter Attia to discuss primary prevention of cardiovascular disease. He argues for targeting causal drivers like LDL early in life and reviews the surprising history of CETP inhibitors—how the HDL-raising hypothesis failed and led to the LDL-lowering drug obicetrapib. They then explore obicetrapib's potential in Alzheimer's prevention, grounded in APOE4 and CETP genetics, and cover the challenges of DHA delivery to the brain, statin–diabetes risk, and the future of clinical trials with AI.

This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.

Canon

•
LDL Is Causally Linked to Atherosclerotic Cardiovascular Disease34:30
Davidson reviews the overwhelming evidence that LDL, particularly apoB-containing particles, directly causes atherosclerosis and that lowering it reduces cardiovascular events proportionally.
ClaudeChatGPTGemini
•
Statin Use and Diabetes Risk: A Trade-Off1:41:15
Davidson discusses the small but real increase in type 2 diabetes risk associated with statin therapy, balancing it against the substantial cardiovascular benefits.
ClaudeChatGPTGemini

Novel

•
Obicetrapib for Alzheimer's Prevention: APOE4 and CETP Link1:03:45
Davidson presents the rationale for using the CETP inhibitor obicetrapib in Alzheimer's disease, based on the genetics of APOE4 and CETP and supported by early biomarker data.
ClaudeChatGPTGemini

Highlights

•
Primary Prevention Should Target Causal Drivers, Not Just Near-Term Risk09:30
Davidson emphasizes that prevention of cardiovascular disease must focus on causal drivers like LDL rather than waiting for a high short-term risk score.
ClaudeChatGPTGemini
•
CETP Inhibitor Story: From HDL Raising to LDL Lowering15:00
The decades-long pursuit of CETP inhibitors initially aimed at raising HDL turned out to be misguided; obicetrapib's success showed that the real benefit comes from lowering LDL.
ClaudeChatGPTGemini

Misc

✧Davidson shares how a family history of heart disease steered him toward lipidology and preventive cardiology.
✧The CETP inhibitor graveyard includes high-profile failures from Pfizer, Roche, Lilly, and Merck, all aiming to raise HDL, but only lowering LDL ultimately proved beneficial.
✧A pilot study found that obicetrapib reduced p-tau 217 in the cerebrospinal fluid, hinting at a disease-modifying effect in Alzheimer's.
Was this useful?